Lil­ly di­vests low blood sug­ar res­cue treat­ment for $500M as in­dus­try fo­cus­es on deal­mak­ing

As all eyes are on Big Phar­ma earn­ings sea­son this week to see what drug­mak­ers are buy­ing, Eli Lil­ly is sell­ing.

The In­di­anapo­lis drug­mak­er an­nounced Mon­day that it will di­vest Baqsi­mi, its nasal treat­ment for se­vere hy­po­glycemia in peo­ple with di­a­betes. The res­cue treat­ment was launched by Lil­ly in 2019 and racked up $139.3 mil­lion in sales last year, the com­pa­ny said, and is avail­able in 27 coun­tries.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER